1148 related articles for article (PubMed ID: 31478503)
21. Extracellular vesicles as modifiers of antibody-drug conjugate efficacy.
Barok M; Puhka M; Yazdi N; Joensuu H
J Extracell Vesicles; 2021 Feb; 10(4):e12070. PubMed ID: 33613875
[TBL] [Abstract][Full Text] [Related]
22. Cysteine-Based Coupling: Challenges and Solutions.
You J; Zhang J; Wang J; Jin M
Bioconjug Chem; 2021 Aug; 32(8):1525-1534. PubMed ID: 34105345
[TBL] [Abstract][Full Text] [Related]
23. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.
Donaghy H
MAbs; 2016; 8(4):659-71. PubMed ID: 27045800
[TBL] [Abstract][Full Text] [Related]
24. Fate of Antibody-Drug Conjugates in Cancer Cells.
Chalouni C; Doll S
J Exp Clin Cancer Res; 2018 Feb; 37(1):20. PubMed ID: 29409507
[TBL] [Abstract][Full Text] [Related]
25. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
[TBL] [Abstract][Full Text] [Related]
26. Catabolism of antibody drug conjugates and characterization methods.
Shadid M; Bowlin S; Bolleddula J
Bioorg Med Chem; 2017 Jun; 25(12):2933-2945. PubMed ID: 28438386
[TBL] [Abstract][Full Text] [Related]
27. Advances with antibody-drug conjugates in breast cancer treatment.
Abdus Subhan M; Torchilin VP
Eur J Pharm Biopharm; 2021 Dec; 169():241-255. PubMed ID: 34748933
[TBL] [Abstract][Full Text] [Related]
28. Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates.
Xu S
Pharm Res; 2015 Nov; 32(11):3577-83. PubMed ID: 26108878
[TBL] [Abstract][Full Text] [Related]
29. Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes.
Abdollahpour-Alitappeh M; Lotfinia M; Gharibi T; Mardaneh J; Farhadihosseinabadi B; Larki P; Faghfourian B; Sepehr KS; Abbaszadeh-Goudarzi K; Abbaszadeh-Goudarzi G; Johari B; Zali MR; Bagheri N
J Cell Physiol; 2019 May; 234(5):5628-5642. PubMed ID: 30478951
[TBL] [Abstract][Full Text] [Related]
30. PEG Linker Improves Antitumor Efficacy and Safety of Affibody-Based Drug Conjugates.
Li Q; Li W; Xu K; Xing Y; Shi H; Jing Z; Li S; Hong Z
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33546481
[TBL] [Abstract][Full Text] [Related]
31. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
32. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates.
Jackson D; Stover D
Pharm Res; 2015 Nov; 32(11):3458-69. PubMed ID: 25339341
[TBL] [Abstract][Full Text] [Related]
33. Antibody-targeted drugs and drug resistance--challenges and solutions.
Shefet-Carasso L; Benhar I
Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
[TBL] [Abstract][Full Text] [Related]
34. Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy.
Joubert N; Denevault-Sabourin C; Bryden F; Viaud-Massuard MC
Eur J Med Chem; 2017 Dec; 142():393-415. PubMed ID: 28911823
[TBL] [Abstract][Full Text] [Related]
35. Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads.
Aguiar S; Dias J; Manuel AM; Russo R; Gois PMP; da Silva FA; Goncalves J
Adv Protein Chem Struct Biol; 2018; 112():143-182. PubMed ID: 29680236
[TBL] [Abstract][Full Text] [Related]
36. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
37. Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes.
Ma Y; Dela Cruz-Chuh J; Khojasteh SC; Dragovich PS; Pillow TH; Zhang D
Drug Metab Dispos; 2019 Aug; 47(8):884-889. PubMed ID: 31072822
[TBL] [Abstract][Full Text] [Related]
38. Investigational antibody-drug conjugates in clinical trials for the treatment of breast cancer.
Okines AFC; Ulrich L
Expert Opin Investig Drugs; 2021 Aug; 30(8):789-795. PubMed ID: 34114911
[No Abstract] [Full Text] [Related]
39. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.
Malik P; Phipps C; Edginton A; Blay J
Pharm Res; 2017 Dec; 34(12):2579-2595. PubMed ID: 28924691
[TBL] [Abstract][Full Text] [Related]
40. Recent Advances in Site Specific Conjugations of Antibody Drug Conjugates (ADCs).
Gao W; Zhang J; Xiang J; Zhang L; Wu C; Dhal PK; Chen B
Curr Cancer Drug Targets; 2016; 16(6):469-79. PubMed ID: 27174056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
